Effect of Residual Retinal Fluid on Visual Function in Ranibizumab-Treated Neovascular Age-Related Macular Degeneration-Reference-Cited by-同舟云学术

Effect of Residual Retinal Fluid on Visual Function in Ranibizumab-Treated Neovascular Age-Related Macular Degeneration

Published:2022-01 Issue: Volume:233 Page:8-17
ISSN:0002-9394
Container-title:American Journal of Ophthalmology
language:en
Short-container-title:American Journal of Ophthalmology

Author:

Holekamp Nancy M.,Sadda Srinivas^ORCID,Sarraf David,Guymer Robyn,Hill Lauren,Blotner Steve,Spicer Galin,Gune Shamika

Funder

Genentech

Allergan

Publisher

Elsevier BV

Subject

Ophthalmology

Reference24 articles.

1. American Academy of Ophthalmology Preferred Practice Pattern Retina/Vitreous Committee. Age-related macular degeneration preferred practice pattern. Accessed December 29, 2020. https://www.aao.org/preferred-practice-pattern/age-related-macular-degeneration-ppp

2. Long-term visual outcomes of intravitreal ranibizumab treatment for wet age-related macular degeneration and effect on blindness rates in south-east Scotland;Borooah;Eye (Lond),2015

3. Estimated cases of legal blindness and visual impairment avoided using ranibizumab for choroidal neovascularization: non-Hispanic white population in the United States with age-related macular degeneration;Bressler;Arch Ophthalmol,2011

4. Real-world outcomes of anti–vascular endothelial growth factor therapy in neovascular age-related macular degeneration in the United States;Ciulla;Ophthalmol Retina,2018

5. Changes in visual acuity in patients with wet age-related macular degeneration treated with intravitreal ranibizumab in daily clinical practice: the LUMIERE study;Cohen;Retina,2013

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Compartmental Exudative Dynamics in Neovascular Age-Related Macular Degeneration;Ophthalmology Retina;2024-08

2. Impact of residual retinal fluid on treatment outcomes in neovascular age-related macular degeneration;British Journal of Ophthalmology;2024-07-20

3. Supplemental Intravitreal Ranibizumab Injections in Eyes Treated with the Port Delivery System with Ranibizumab in the Archway Trial;Ophthalmology Retina;2024-06

4. Intravitreal treatments for exudative maculopathies: the efficacy/durability dilemma;Minerva Ophthalmology;2024-04

5. Impact of Prolonged Persisting Subretinal Fluid on the Outcome of Aflibercept Treatment in Neovascular Age-Related Macular Degeneration;Journal of Ocular Pharmacology and Therapeutics;2024-03-01